**Question:** Drug used for obesity: (PGI June 2008)

A. Orlistat
B. Metformin
C. Thyroxine
D. Bromocriptine

**Core Concept:**
Obesity is a condition characterized by excessive body fat accumulation, which can lead to various health issues. Treatment options for obesity involve lifestyle modifications, behavioral therapies, and pharmacotherapy. The four options provided represent different drugs commonly used in the management of obesity.

**Why the Correct Answer is Right:**

**A. Orlistat:** Orlistat (Xenical) is a lipase inhibitor that blocks the absorption of dietary fat. By preventing the digestion and absorption of fats, Orlistat reduces caloric intake and results in weight loss. It is specifically indicated for patients with a BMI greater than 30 kg/m2 or BMI greater than 28 kg/m2 with comorbidities.

**Why Each Wrong Option is Incorrect:**

**B. Metformin:** Metformin (Glucophage) is primarily an antidiabetic drug used in the treatment of type 2 diabetes mellitus. Although it may have some weight loss effects, it is not primarily indicated for obesity treatment.

**C. Thyroxine:** Thyroxine (T4) is a thyroid hormone used for hypothyroidism treatment, not obesity management. Overactive thyroid (hyperthyroidism) may cause weight loss, while underactive thyroid (hypothyroidism) is associated with weight gain. In obesity treatment, levothyroxine is not the correct drug choice.

**D. Bromocriptine:** Bromocriptine (Parlodel) is a dopamine agonist primarily used in the treatment of Parkinson's disease, acromegaly, and hyperprolactinemia. Although it may cause weight loss, it is not a first-line medication for obesity management.

**Why Each Wrong Option is Incorrect:**

**D. Bromocriptine:** Bromocriptine (Parlodel) is a dopamine agonist primarily used in the treatment of Parkinson's disease, acromegaly, and hyperprolactinemia. Although it may cause weight loss, it is not a first-line medication for obesity management.

**Clinical Pearls:**

1. Orlistat is a first-line medication for obesity treatment due to its proven efficacy in reducing body weight and improving obesity-related co-morbidities.
2. Metformin can contribute to weight loss, but it is not specifically targeted for obesity treatment.
3. Thyroxine should be avoided in obesity management as it is intended for hypothyroidism treatment, which may lead to unintended weight loss.
4. Bromocriptine is primarily used for disorders like Parkinson's disease, acromegaly, and hyperprolactinemia, not obesity.

In summary, Orlistat is the correct choice among these options, as it is specifically designed to address obesity by inhibiting fat absorption. While metformin and bromocriptine may cause unintended weight loss, they